Main Navigation

GangaGen

Home

Search for:

GangaGen Secures additional US$7.9 Million from CARB-X for Pre-clinical Development of Novel Klebicins Targeting Nosocomial Pneumonia caused by Multidrug-resistant Klebsiella pneumoniae
GangaGen Achieves Initial CARB-X Milestone for Klebicin Program Targeting Pneumonia caused by Multidrug-resistant Klebsiella pneumoniae Bacteria and Secures US$2.1 Million for Lead Optimization
Exciting Sports Day at GangaGen
GangaGen Celebrates Employee Achievements
(no title)